Literature DB >> 17046188

Roadside detection of impairment under the influence of ketamine--evaluation of ketamine impairment symptoms with reference to its concentration in oral fluid and urine.

Wing-Chi Cheng1, Kin-Man Ng, Ka-Keung Chan, Vincent King-Kuen Mok, Ben Kin-Leung Cheung.   

Abstract

Although there are many roadside testing devices available for the screening of abused drugs, none of them can be used for the detection of ketamine, a popular abused drug in Hong Kong. In connection to local drug driving legislation, effective roadside detection of ketamine in suspected drug-impaired drivers has to be established. According to the drug evaluation and classification program (DEC), ketamine is classified in the phencyclidine (PCP) category. However, no study has been performed regarding the signs and symptoms exhibited by users under the influence of ketamine. In a study to develop a protocol for effective roadside detection of drug-impaired drivers, 62 volunteers exiting from discos were assessed using field impairment tests (FIT) that included measurements of three vital signs (i.e. body temperature, pulse rate and blood pressure), three eye examinations [pupil size, lack of convergence (LOC) and horizontal gaze nystagmus (HGN)] and four divided attention tests (Romberg, one-leg stand, finger-to-nose and walk-and-turn tests). Subsequent laboratory analysis of oral fluid and urine samples from the participants revealed the presence of common abused drugs in both the urine and oral fluid samples of 55 subjects. The remaining 7 subjects with no drug in their oral fluid samples were used as drug-free subjects. In addition, 10 volunteers from the laboratory who were regarded as drug-free subjects were also assessed using the same FIT. Among the 62 volunteers, 39 of them were detected with ketamine in their oral fluid. Of these ketamine users, 21 of them (54%) with only ketamine found in their oral fluid samples while the rest (18 subjects) of them had other drugs (i.e. MA, MDMA, benzodiazepines and/or THC) in addition to ketamine. Of the 21 ketamine-only users, 15 of them (71%) were successfully identified by FIT. It was found that when salivary ketamine concentrations were greater than 300 ng/mL, signs of impairment became evident, with over 90% detection rate using the FIT. By comparing the FIT observations on the 21 ketamine-only users with the drug-free subjects, the typical signs and symptoms observable for subjects under the influence of ketamine included LOC, HGN, elevated pulse rate and in general, failing the divided attention tests, especially the walk-and-turn and one-leg stand.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17046188     DOI: 10.1016/j.forsciint.2006.09.001

Source DB:  PubMed          Journal:  Forensic Sci Int        ISSN: 0379-0738            Impact factor:   2.395


  5 in total

1.  A methoxydiphenidine-impaired driver.

Authors:  Nicole Stachel; Andrea Jacobsen-Bauer; Gisela Skopp
Journal:  Int J Legal Med       Date:  2015-10-19       Impact factor: 2.686

2.  Simultaneous liquid chromatography-mass spectrometry quantification of urinary opiates, cocaine, and metabolites in opiate-dependent pregnant women in methadone-maintenance treatment.

Authors:  Diaa M Shakleya; Riet Dams; Robin E Choo; Hendree Jones; Marilyn A Huestis
Journal:  J Anal Toxicol       Date:  2010 Jan-Feb       Impact factor: 3.367

3.  Clinical and behavior characteristics of individuals who used ketamine.

Authors:  Tony Szu-Hsien Lee; Yi-Hsuan Liu; Yun-Ju Huang; Wai-Kwong Tang; Yifan Wang; Sien Hu; Ching-Po Lin; Chiang-Shan Ray Li; Chia-Chun Hung
Journal:  Sci Rep       Date:  2022-01-17       Impact factor: 4.379

4.  The effects of different doses of ketamine on quality of normal ejaculated sperm.

Authors:  Forouzan Absalan; Alireza Ghannadi; Abdollah Zabihi
Journal:  Int J Fertil Steril       Date:  2014-07-08

5.  Gender differences in subjective discontinuation symptoms associated with ketamine use.

Authors:  Wen-Yin Chen; Ming-Chyi Huang; Shih-Ku Lin
Journal:  Subst Abuse Treat Prev Policy       Date:  2014-09-22
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.